🇺🇸 FDA
Patent

US 8962824

Composition of novel carbohydrate drug for treatment of human diseases

granted A61KA61K31/70A61K31/715

Quick answer

US patent 8962824 (Composition of novel carbohydrate drug for treatment of human diseases) held by GALECTIN THERAPEUTICS, INC. expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GALECTIN THERAPEUTICS, INC.
Grant date
Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/70, A61K31/715, A61K31/738, A61K45/06